Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:LLY ... trades showed up on publicly available options history that we track here at Benzinga.

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...